Top

Published in:

01-06-2012 | Reproductive Medicine

Clomiphene citrate alternatives for the initial management of polycystic ovary syndrome: an evidence-based approach

Author: Hatem Abu Hashim

Published in: Archives of Gynecology and Obstetrics | Issue 6/2012

Abstract

Polycystic ovary syndrome (PCOS) is a prevalent and heterogeneous condition affecting 4–8% of reproductive age women. It is the most common cause of chronic anovulation and is associated with hyperandrogenemia. Clomiphene citrate (CC) is considered as the first-line therapy for ovulation induction in these patients. Despite progress in understanding the pathophysiology of PCOS over the past 20 years, many questions persist to the extent that PCOS was described as “A Riddle Wrapped in a Mystery inside an Enigma”. On the other hand, a recent publication from the Centers for Disease Control suggested that CC may be associated with an increased risk of birth defects. The purpose of this review is to critically evaluate and summarize the current literature regarding CC alternatives for the initial management of PCOS focusing specifically on the roles of weight loss and other approaches to ovulation induction as insulin-sensitizing drugs, aromatase inhibitors, minimal stimulation protocol, gonadotrophins and surgery (laparoscopic ovarian drilling). Finally, the efficacy of intrauterine insemination with CC for the initial management of PCOS will be evaluated.

Overbeek A, Lambalk CB (2009) Phenotypic and pharmacogenetic aspects of ovulation induction in WHO II anovulatory women. Gynecol Endocrinol 25:222–234. doi:10.1080/09513590802571118 PubMedCrossRef

Brown J, Farquhar C, Beck J, Boothroyd C, Hughes E (2009) Clomiphene and anti-oestrogens for ovulation induction in PCOS. Cochrane Database Syst Rev (4):CD002249. doi:10.1002/14651858.CD002249.pub4

Diamanti-Kandarakis E, Kouli CR, Bergiele AT et al (1999) A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 84:4006–4011. doi:10.1210/jc.84.11.4006 PubMedCrossRef

Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R (1998) Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 83:3078–3082. doi:10.1210/jc.83.9.3078 PubMedCrossRef

Asunción M, Calvo RM, San Millán JL, Sancho J, Avila S, Escobar-Morreale HF (2000) A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 85:2434–2438. doi:10.1210/jc.85.7.2434 PubMedCrossRef

Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO (2004) The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 89:2745–2749. doi:10.1210/jc.2003-032046 PubMedCrossRef

March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ (2010) The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 25:544–551. doi:10.1093/humrep/dep399 PubMedCrossRef

Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group (2008) Consensus on infertility treatment related to polycystic ovary syndrome. Fertil Steril 89:505–522. doi:10.1016/j.fertnstert.2007.09.041 CrossRef

Vause TD, Cheung AP, Sierra S, Society of Obstetricians and Gynaecologists of Canada et al (2010) Ovulation induction in polycystic ovary syndrome: no. 242, May 2010. Int J Gynaecol Obstet 111:95–100. doi:10.1016/j.ijgo.2010.07.001 PubMedCrossRef

10.

Homburg R (2005) Clomiphene citrate-end of an era? A mini-review. Hum Reprod 20:2043–2051. doi:10.1093/humrep/dei042 PubMedCrossRef

11.

Imani B, Eijkemans MJ, te Velde ER, Habbema JD, Fauser BC (2002) A nomogram to predict the probability of live birth after clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. Fertil Steril 77:91–97. doi:10.1016/S0015-0282(01)02929-6 PubMedCrossRef

12.

Messinis IE (2005) Ovulation induction: a mini review. Hum Reprod 20:2688–2697. doi:10.1093/humrep/dei128 PubMedCrossRef

13.

National Collaborating Centre for Women’s and Children’s Health/National Institute for Clinical Excellence (2004) Fertility: assessment and treatment for people with fertility problems. Clinical Guideline No. 11. RCOG Press, London. http://www.nice.org.uk/nicemedia/pdf/CG011niceguideline.pdf

14.

Amer SAK (2008) Laparoscopic ovarian surgery for polycystic ovarian syndrome. In: Dunlop W, Ledger WL (eds) Recent advances in obstetrics and gynaecology, 24th edn. Royal Society of Medicine Press Ltd, London, pp 227–243

15.

Legro RS, Barnhart HX, Schlaff WD, Cooperative Multicenter Reproductive Medicine Network et al (2007) Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med 356:551–566PubMedCrossRef

16.

Gonen Y, Casper RF (1990) Sonographic determination of a possible adverse effect of clomiphene citrate on endometrial growth. Hum Reprod 5:670–674PubMed

17.

Opsahl MS, Robins ED, O’Connor DM, Scott RT, Fritz MA (1996) Characteristics of gonadotropin response, follicular development, and endometrial growth and maturation across consecutive cycles of clomiphene citrate treatment. Fertil Steril 66:533–539PubMed

18.

Nakamura Y, Ono M, Yoshida Y, Sugino N, Ueda K, Kato H (1997) Effects of CC on the endometrial thickness and echogenic pattern of the endometrium. Fertil Steril 67:256–260. doi:10.1016/S0015-0282(97)81907-3 PubMedCrossRef

19.

Dehbashi S, Parsanezhad ME, Alborzi S, Zarei A (2003) Effect of clomiphene citrate on endometrium thickness and echogenic patterns. Int J Gynecol Obstet 80:49–53. doi:10.1016/S0020-7292(02)00341-7 CrossRef

20.

Randall JM, Templeton A (1991) Cervical mucus score and in vitro sperm mucus interaction in spontaneous and CC citrate cycles. Fertil Steril 56:465–468PubMed

21.

Shoham Z, Borenstein R, Lunenfeld B, Pariente C (1990) Hormonal profiles following clomiphene citrate therapy in conception and nonconception cycles. Clin Endocrinol (Oxf) 33:271–278. doi:10.1111/j.1365-2265.1990.tb00491.x CrossRef

22.

Imani B, Eijkemans MJC, te Velde ER, Habbema JD, Fauser BC (1998) Predictors of patients remaining anovulatory during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. J Clin Endocrinol Metab 83:2361–2365. doi:10.1210/jc.83.7.2361 PubMedCrossRef

23.

Imani B, Eijkemans MJ, de Jong FH, Payne NN, Bouchard P, Giudice LC, Fauser BC (2000) Free androgen index and leptin are the most prominent endocrine predictors of ovarian response during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. J Clin Endocrinol Metab 85:676–682. doi:10.1210/jc.85.2.676 PubMedCrossRef

24.

Parsanezhad ME, Alborzi S, Zarei A, Dehbashi S, Omrani G (2001) Insulin resistance in clomiphene responders and nonresponders with polycystic ovarian disease and therapeutic effects of metformin. Int J Gynaecol Obstet 75:43–50. doi:10.1016/S0020-7292(01)00470-2 PubMedCrossRef

25.

Overbeek A, Kuijper EA, Hendriks ML et al (2009) Clomiphene citrate resistance in relation to follicle-stimulating hormone receptor Ser680Ser-polymorphism in polycystic ovary syndrome. Hum Reprod 24:2007–2013. doi:10.1093/humrep/dep114 PubMedCrossRef

26.

Padmanabhan V (2009) Polycystic ovary syndrome—“A Riddle Wrapped in a Mystery inside an Enigma”. J Clin Endocrinol Metab 94:1883–1885. doi:10.1210/jc.2009-0492 PubMedCrossRef

27.

Reefhuis J, Honein MA, Schieve LA, Rasmussen SA, National Birth Defects Prevention Study (2011) Use of clomiphene citrate and birth defects, National Birth Defects Prevention Study, 1997–2005. Hum Reprod 26:451–457. doi:10.1093/humrep/deq313 PubMedCrossRef

28.

Al-Azemi M, Omu FE, Omu AE (2004) The effect of obesity on the outcome of infertility management in women with polycystic ovary syndrome. Arch Gynecol Obstet 270:205–210. doi:10.1007/s00404-003-0537-2 PubMedCrossRef

29.

Norman RJ, Noakes M, Wu R, Davies MJ, Moran L, Wang JX (2004) Improving reproductive performance in overweight/obese women with effective weight management. Hum Reprod Update 10:267–280. doi:10.1093/humupd/dmh018 PubMedCrossRef

30.

Norman RJ, Davies MJ, Lord J, Moran LJ (2002) The role of lifestyle modification in polycystic ovary syndrome. Trends Endocrinol Metab 13:251–257. doi:10.1016/S1043-2760(02)00612-4 PubMedCrossRef

31.

Hoeger KM (2007) Obesity and lifestyle management in polycystic ovary syndrome. Clin Obstet Gynecol 50:277–294. doi:10.1097/GRF.0b013e31802f54c8 PubMedCrossRef

32.

Pasquali R, Gambineri A, Pagotto U (2006) The impact of obesity on reproduction in women with polycystic ovary syndrome. BJOG 113:1148–1159. doi:10.1111/j.1471-0528.2006.00990.x PubMedCrossRef

33.

Tolino A, Gambardella V, Caccavale C et al (2005) Evaluation of ovarian functionality after a dietary treatment in obese women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 119:87–93. doi:10.1016/j.ejogrb.2004.06.043 PubMedCrossRef

34.

Moran LJ, Pasquali R, Teede HJ, Hoeger KM, Norman RJ (2009) Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society. Fertil Steril 92:1966–1982. doi:10.1016/j.fertnstert.2008.09.018 PubMedCrossRef

35.

Moran LJ, Hutchison SK, Norman RJ, Teede HJ (2011) Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev (2):CD007506. doi:10.1002/14651858.CD007506.pub2

36.

Stamets K, Taylor DS, Kunselman A, Demers LM, Pelkman CL, Legro RS (2004) A randomized trial of the effects of two types of short-term hypocaloric diets on weight loss in women with polycystic ovary syndrome. Fertil Steril 81:630–637. doi:10.1016/j.fertnstert.2003.08.023 PubMedCrossRef

37.

Moran LJ, Noakes M, Clifton PM, Tomlinson L, Galletly C, Norman RJ (2003) Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab 88:812–819. doi:10.1210/jc.2002-020815 PubMedCrossRef

38.

Poehlman ET, Dvorak RV, DeNino WF, Brochu M, Ades PA (2000) Effects of resistance training and endurance training on insulin sensitivity in nonobese, young women: a controlled randomized trial. J Clin Endocrinol Metab 85:2463–2468. doi:10.1210/jc.85.7.2463 PubMedCrossRef

39.

Palomba S, Falbo A, Giallauria F et al (2010) Six weeks of structured exercise training and hypocaloric diet increases the probability of ovulation after clomiphene citrate in overweight and obese patients with polycystic ovary syndrome: a randomized controlled trial. Hum Reprod 25:2783–2791. doi:10.1093/humrep/deq254 PubMedCrossRef

40.

Otta CF, Wior M, Iraci GS et al (2010) Clinical, metabolic, and endocrine parameters in response to metformin and lifestyle intervention in women with polycystic ovary syndrome: a randomized, double-blind, and placebo control trial. Gynecol Endocrinol 26:173–178. doi:10.3109/09513590903215581 PubMedCrossRef

41.

Karimzadeh MA, Javedani M (2010) An assessment of lifestyle modification versus medical treatment with clomiphene citrate, metformin, and clomiphene citrate-metformin in patients with polycystic ovary syndrome. Fertil Steril 94:216–220. doi:10.1016/j.fertnstert.2009.02.078 PubMedCrossRef

42.

Alvarez-Blasco F, Botella-Carretero JI, San Millán JL, Escobar-Morreale HF (2006) Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women. Arch Intern Med 166:2081–2086PubMedCrossRef

43.

Escobar-Morreale HF, Botella-Carretero JI, Alvarez-Blasco F, Sancho J, San Millán JL (2005) The polycystic ovary syndrome associated with morbid obesity may resolve after weight loss induced by bariatric surgery. J Clin Endocrinol Metab 90:6364–6369. doi:10.1210/jc.2005-1490 PubMedCrossRef

44.

Jayagopal V, Kilpatrick ES, Holding S, Jennings PE, Atkin SL (2005) Orlistat is as beneficial as metformin in the treatment of polycystic ovarian syndrome. J Clin Endocrinol Metab 90:729–733. doi:10.1210/jc.2004-0176 PubMedCrossRef

45.

Sabuncu T, Harma M, Harma M, Nazligul Y, Kilic F (2003) Sibutramine has a positive effect on clinical and metabolic parameters in obese patients with polycystic ovary syndrome. Fertil Steril 80:1199–1204. doi:10.1016/S0015-0282(03)02162-9 PubMedCrossRef

46.

Legro RS, Castracane VD, Kauffman RP (2004) Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls. Obstet Gynecol Surv 59:141–154PubMedCrossRef

47.

Diamanti-Kandarakis E, Christakou CD, Kandaraki E, Economou FN (2010) Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome. Eur J Endocrinol 162:193–212. doi:10.1530/EJE-09-0733 PubMedCrossRef

48.

Franks S (2011) When should an insulin sensitizing agent be used in the treatment of polycystic ovary syndrome? Clin Endocrinol (Oxf) 74:148–151. doi:10.1111/j.1365-2265.2010.03934.x CrossRef

49.

Johnson N (2011) Metformin is a reasonable first-line treatment option for non-obese women with infertility related to anovulatory polycystic ovary syndrome—a meta-analysis of randomised trials. Aust N Z J Obstet Gynaecol 51:125–129. doi:10.1111/j.1479-828X.2010.01274.x PubMedCrossRef

50.

Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH (2010) Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, d-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev (1):CD003053. doi:10.1002/14651858.CD003053.pub4

51.

Mauri D, Pavlidis N, Polyzos NP, Ioannidis JP (2006) Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. J Natl Cancer Inst 98:1285–1291. doi:10.1093/jnci/djj357 PubMedCrossRef

52.

Mitwally FM, Casper RF (2001) Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertil Steril 75:305–309. doi:10.1016/S0015-0282(00)01705-2 PubMedCrossRef

53.

Casper RF, Mitwally MF (2006) Review: aromatase inhibitors for ovulation induction. J Clin Endocrinol Metab 91:760–771. doi:10.1210/jc.2005-1923 PubMedCrossRef

54.

Casper RF (2009) Letrozole versus clomiphene citrate: which is better for ovulation induction? Fertil Steril 92:858–859. doi:10.1016/j.fertnstert.2007.03.094 PubMedCrossRef

55.

Pritts EA (2010) Letrozole for ovulation induction and controlled ovarian hyperstimulation. Curr Opin Obstet Gynecol 22:289–294. doi:10.1097/GCO.0b013e32833beebf PubMed

56.

Lee VC, Ledger W (2011) Aromatase inhibitors for ovulation induction and ovarian stimulation. Clin Endocrinol (Oxf) 74:537–546. doi:10.1111/j.1365-2265.2011.04006.x CrossRef

57.

He D, Jiang F (2011) Meta-analysis of letrozole versus clomiphene citrate in polycystic ovary syndrome. Reprod Biomed Online 23:91–96. doi:10.1016/j.rbmo.2011.03.024 PubMedCrossRef

58.

Yang MQ, Quan S, Li H, Song YL, Xing FQ (2008) Effect of two different doses of letrozole in promoting ovulation in infertile women with polycystic ovarian syndrome. Nan Fang Yi Ke Da Xue Xue Bao 28:2060–2061PubMed

59.

Ramezanzadeh F, Nasiri R, Sarafraz Yazdi M, Baghrei M (2011) A randomized trial of ovulation induction with two different doses of letrozole in women with PCOS. Arch Gynecol Obstet 284:1029–1034. doi:10.1007/s00404-011-1951-5 PubMedCrossRef

60.

Tredway DR, Schertz JC (2011) Anastrozole versus clomiphene citrate: which is better for ovulation induction? Fertil Steril 95:1549–1551. doi:10.1016/j.fertnstert.2010.07.1094 PubMedCrossRef

61.

Biljan MM, Hemmings R, Brassard N (2005) The outcome of 150 babies following the treatment with letrozole or letrozole and gonadotropins. Fertil Steril 84(suppl 1):S95CrossRef

62.

Forman R, Gill S, Moretti M, Tulandi T, Koren G, Casper R (2007) Fetal safety of letrozole and clomiphene citrate for ovulation induction. J Obstet Gynaecol Can 29:668–671PubMed

63.

Tulandi T, Martin J, Al-Fadhli R et al (2006) Congenital malformations among 911 newborns conceived after infertility treatment with letrozole or clomiphene citrate. Fertil Steril 85:1761–1765. doi:10.1016/j.fertnstert.2006.03.014 PubMedCrossRef

64.

Badawy A, Shokeir T, Allam AF, Abdelhady H (2009) Pregnancy outcome after ovulation induction with aromatase inhibitors or clomiphene citrate in unexplained infertility. Acta Obstet Gynecol Scand 88:187–191. doi:10.1080/00016340802638199 PubMedCrossRef

65.

Felemban A, Lin Tan S, Tulandi T (2000) Laparoscopic treatment of polycystic ovaries with insulated needle cautery: a reappraisal. Fertil Steril 73:266–269. doi:10.1016/S0015-0282(99)00534-8 PubMedCrossRef

66.

Mercorio F, Mercorio A, Di Spiezio Sardo A, Barba GV, Pellicano M, Nappi C (2008) Evaluation of ovarian adhesion formation after laparoscopic ovarian drilling by second-look minilaparoscopy. Fertil Steril 89:1229–1233. doi:10.1016/j.fertnstert.2007.05.009 PubMedCrossRef

67.

Api M (2009) Is ovarian reserve diminished after laparoscopic ovarian drilling? Gynecol Endocrinol 25:159–165. doi:10.1080/09513590802585605 PubMedCrossRef

68.

Cleemann L, Lauszus FF, Trolle B (2004) Laparoscopic ovarian drilling as first line of treatment in infertile women with polycystic ovary syndrome. Gynecol Endocrinol 18:138–143. doi:10.1080/09513590410001667869 PubMedCrossRef

69.

Amer SA, Li TC, Metwally M, Emarh M, Ledger WL (2009) Randomized controlled trial comparing laparoscopic ovarian diathermy with clomiphene citrate as a first-line method of ovulation induction in women with polycystic ovary syndrome. Hum Reprod 24:219–225. doi:10.1093/humrep/den325 PubMedCrossRef

70.

Abu Hashim H, Foda O, Ghayaty E, Elawa A (2011) Laparoscopic ovarian diathermy after clomiphene failure in polycystic ovary syndrome: is it worthwhile? A randomized controlled trial. Arch Gynecol Obstet 284:1303–1309. doi:10.1007/s00404-011-1983-x PubMedCrossRef

71.

Tummon I, Gavrilova-Jordan L, Allemand MC, Session D (2005) Polycystic ovaries and ovarian hyperstimulation syndrome: a systematic review. Acta Obstet Gynecol Scand 84:611–616. doi:10.1111/j.0001-6349.2005.00788.x PubMed

72.

Van Der Meer M, Hompes PG, De Boer JA, Schats R, Schoemaker J (1998) Cohort size rather than follicle-stimulating hormone threshold level determines ovarian sensitivity in polycystic ovary syndrome. J Clin Endocrinol Metab 83:423–426. doi:10.1210/jc.83.2.423 CrossRef

73.

Cristello F, Cela V, Artini PG, Genazzani AR (2005) Therapeutic strategies for ovulation induction in infertile women with polycystic ovary syndrome. Gynecol Endocrinol 21:340–352. doi:10.1080/09513590500463360 PubMedCrossRef

74.

Homburg R, Insler V (2002) Ovulation induction in perspective. Hum Reprod Update 8:449–462. doi:10.1093/humupd/8.5.449 PubMedCrossRef

75.

Homburg R, Howles CM (1999) Low-dose FSH therapy for anovulatory infertility associated with polycystic ovary syndrome: rationale, reflections and refinements. Hum Reprod Update 5:493–499. doi:10.1093/humupd/5.5.493 PubMedCrossRef

76.

White DM, Polson DW, Kiddy D, Sagle P, Watson H, Gilling-Smith C, Hamilton-Fairley D, Franks S (1996) Induction of ovulation with low-dose gonadotropins in polycystic ovary syndrome: an analysis of 109 pregnancies in 225 women. J Clin Endocrinol Metab 81:3821–3824. doi:10.1210/jc.81.11.3821 PubMedCrossRef

77.

Yarali H, Zeyneloglu HB (2004) Gonadotrophin treatment in patients with polycystic ovary syndrome. Reprod Biomed Online 8:528–537. doi:10.1016/S1472-6483(10)61099-1 PubMedCrossRef

78.

López E, Gunby J, Daya S, Parrilla JJ, Abad L, Balasch J (2004) Ovulation induction in women with polycystic ovary syndrome: randomized trial of clomiphene citrate versus low-dose recombinant FSH as first line therapy. Reprod Biomed Online 9:382–390. doi:10.1016/S1472-6483(10)61273-4 PubMedCrossRef

79.

Corfman RS, Ory SJ, Milad MP, Erickson LD, Bellevance TL, Ball GD (1993) A novel ovarian stimulation protocol for use with assisted reproductive technologies. Fertil Steril 60:864–870PubMed

80.

Lu PY, Lee SH, Chen ALJ, Erickson LD, Atkinson EJ, Ory SJ (1996) Minimal stimulation achieves pregnancy rates comparable to human menopausal gonadotropins in the treatment of infertility. Fertil Steril 65:583–587PubMed

81.

Abu Hashim H, Bazeed M, Abd Elaal I (2012) Minimal stimulation or clomiphene citrate as first line therapy in women with polycystic ovary syndrome: a randomized controlled trial. Gynecol Endocrinol. 28:87–90. doi:10.3109/09513590.2011.589924

82.

Mukherjee S, Sharma S, Chakravarty BN (2010) Comparative evaluation of pregnancy outcome in gonadotrophin-clomiphene combination vs clomiphene alone in polycystic ovarian syndrome and unexplained infertility—a prospective clinical trial. J Hum Reprod Sci 3:80–84. doi:10.4103/0974-1208.69341 PubMedCrossRef

83.

Aboulghar M, Baird DT, Collins J, ESHRE Capri Workshop Group et al (2009) Intrauterine insemination. Hum Reprod Update 15:265–277. doi:10.1093/humupd/dmp003 CrossRef

84.

Abdelkader AM, Yeh J (2009) The potential use of intrauterine insemination as a basic option for infertility: a review for technology-limited medical settings. Obstet Gynecol Int 2009:584837. doi:10.1155/2009/584837 PubMed

85.

Abu Hashim H, Ombar O, Abd Elaal I (2011) Intrauterine insemination versus timed intercourse with clomiphene citrate in polycystic ovary syndrome: a randomized controlled trial. Acta Obstet Gynecol Scand 90:344–350. doi:10.1111/j.1600-0412.2010.01063.x PubMedCrossRef

Title: Clomiphene citrate alternatives for the initial management of polycystic ovary syndrome: an evidence-based approach
Author: Hatem Abu Hashim
Publication date: 01-06-2012
Publisher: Springer-Verlag
Published in: Archives of Gynecology and Obstetrics / Issue 6/2012
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-012-2261-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Clomiphene citrate alternatives for the initial management of polycystic ovary syndrome: an evidence-based approach

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2012

p53 codon 72 polymorphism and endometriosis: a meta-analysis

Analysis of the effectiveness of visual inspection with acetic acid/Lugol’s iodine in one-time and annual follow-up screening in rural China

Peritoneal relative to venous serum biomarker concentrations for diagnosis of ectopic pregnancy

Rapamycin and a hyaluronic acid-carboxymethylcellulose membrane did not lead to reduced adhesion formations in a rat abdominal adhesion model

The etiology of maternal mortality in developed countries: a systematic review of literature

Appropriate interval between endometrial polyp resection and the proceeding IVF start